Charles River Laboratories extended its run of acquisitions with a $585 million buyout of WIL Research, picking up a company the CRO said will expand its global footprint and bolster its manufacturing capabilities.
CRO Charles River Laboratories has expanded its relationship with the Michael J. Fox Foundation for Parkinson's Research to investigate a promising target that could lead to new treatments for the disease.
Charles River Laboratories, on the heels of some M&A-driven revenue growth, acquired another early-stage research company, paying $36 million for a German provider of drug discovery services.
Charles River Laboratories returned to revenue growth on a wave of dealmaking, lifting its full-year guidance in response.
Preclinical CRO Charles River Laboratories brought in three new discovery contracts with outfits funded by the Wellcome Trust, lending its expertise in early-stage drug development.
Charles River Laboratories saw its sales dip in the second quarter, but the early-stage specialist is counting on some recent acquisitions to spur growth for the full year.
Charles River Laboratories International expects to boost its position in pharma manufacturing with a $212 million deal to buy Celsis International, a company that specializes in endotoxin and microbial detection (EMD).
Charles River Laboratories' longtime chief financial officer is stepping down in a planned retirement, giving the preclinical CRO a chance to further integrate its recent acquisitions and increase its focus on drug discovery.
CRO giant Charles River Laboratories ended 2014 with a bang, boosting revenue by about 14% in the fourth quarter to close a deal-filled year.
Charles River Laboratories has extended its partnership with CHDI Foundation, signing up for 5 more years of work spotlighting new treatments for Huntington's disease.